New insights in the expression of stromal caveolin 1 in breast cancer spread to axillary lymph nodes.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 02 2021
02 02 2021
Historique:
received:
09
05
2020
accepted:
19
01
2021
entrez:
3
2
2021
pubmed:
4
2
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Recent evidence suggests that a loss of expression of caveolin in the stromal compartment (sCav-1) of human invasive breast carcinoma (IBC) may be a predictor of disease recurrence, metastasis and poor outcome. At present, there is little knowledge regarding the expression of sCav-1 at the metastatic sites. We therefore studied sCav-1 expression in IBCs and in their axillary lymph nodes to seek a correlation with cancer metastasis. 189 consecutive invasive IBCs (53 with axillary lymph node metastases and 136 without) were studied by immunohistochemistry, using a rabbit polyclonal anti-Cav-1 antibody. In IBCs sCav-1 was evaluated in fibroblasts scattered in the tumor stroma whereas in lymph nodes sCav-1 was assessed in fibroblast-like stromal cells. For the first time, we observed a statistically significant progressive loss of sCav-1 from normal/reactive axillary lymph nodes of tumors limited to the breast to metastatic axillary lymph nodes, through normal/reactive axillary lymph nodes of tumors with axillary metastatic spread. These data indicate that Cav-1 expressed by the stromal compartment of lymph nodes, somehow, may possibly contribute to metastatic spread in IBC.
Identifiants
pubmed: 33531603
doi: 10.1038/s41598-021-82405-y
pii: 10.1038/s41598-021-82405-y
pmc: PMC7854652
doi:
Substances chimiques
CAV1 protein, human
0
Caveolin 1
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2755Références
Oncogene. 1999 Mar 11;18(10):1881-90
pubmed: 10086342
Ann Med. 2004;36(8):584-95
pubmed: 15768830
Cancer Biol Ther. 2010 Jul 15;10(2):135-43
pubmed: 20431349
Nat Rev Cancer. 2006 May;6(5):392-401
pubmed: 16572188
Cancer Metastasis Rev. 2012 Dec;31(3-4):429-40
pubmed: 22699312
Pathol Oncol Res. 2018 Jan;24(1):59-65
pubmed: 28236153
Cell Cycle. 2011 Jun 1;10(11):1794-809
pubmed: 21521946
Cell Cycle. 2009 Dec;8(23):3984-4001
pubmed: 19923890
Cancer Biol Ther. 2009 Jun;8(11):1071-9
pubmed: 19502809
Cancer Res. 2001 Mar 15;61(6):2361-4
pubmed: 11289096
Nat Med. 2017 Oct;23(10):1176-1190
pubmed: 28920957
Clin Cancer Res. 1998 Aug;4(8):1873-80
pubmed: 9717814
Trends Cell Biol. 1994 Jul;4(7):231-5
pubmed: 14731661
J Cell Sci. 2008 Jul 15;121(Pt 14):2360-71
pubmed: 18577581
Cancer Res. 2001 Jul 1;61(13):5168-78
pubmed: 11431356
Breast Cancer Res Treat. 2012 Jan;131(1):1-15
pubmed: 21901387
Virchows Arch. 2014 Sep;465(3):291-8
pubmed: 24980157
Front Immunol. 2017 Dec 13;8:1794
pubmed: 29326695
World J Surg Oncol. 2007 Oct 03;5:110
pubmed: 17915016
Am J Pathol. 2009 Jun;174(6):2035-43
pubmed: 19411449
FEBS Lett. 2010 May 3;584(9):1923-30
pubmed: 20036661
Oncol Lett. 2014 Oct;8(4):1409-1421
pubmed: 25202343
Breast Cancer Res Treat. 2006 Sep;99(1):85-90
pubmed: 16541313
Cancer Biol Ther. 2008 Aug;7(8):1212-25
pubmed: 18458534
J Biol Chem. 1989 Dec 5;264(34):20163-6
pubmed: 2479645
Clin Cancer Res. 2007 Jan 1;13(1):90-101
pubmed: 17200343
Am J Pathol. 2009 Jun;174(6):2023-34
pubmed: 19411448
Cancers (Basel). 2018 Dec 11;10(12):
pubmed: 30544963
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Br J Cancer. 2008 Jul 22;99(2):327-34
pubmed: 18612310
Semin Cancer Biol. 2012 Jun;22(3):174-86
pubmed: 22374376
Clin Exp Metastasis. 2014 Jun;31(5):511-20
pubmed: 24590865
Cell Rep. 2017 Dec 5;21(10):2842-2854
pubmed: 29212030